Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments.

GB Virus C

High Prevalence of GBV-C in Volunteer Blood Donors in South Africa

A high prevalence of GBV-C hepatitis infection was found in South African blood donors.

"The implications of the high prevalence of GBV-C RNA in the blood donor population in this South African study are uncertain. If GBV-C is shown to play a role in disease, the findings in this study may have important implications for future screening of volunteer blood donor populations, and may affect adversely the available blood supply," wrote Alison Casteling, University of Witwatersrand, South Africa, and colleagues ("GB Virus C Prevalence in Blood Donors and High Risk Groups for Parenterally Transmitted Agents from Gauteng, South Africa," Journal of Medical Virology, 1998;55:103-108).

Both GB virus C (Simons et al., Nature, 1995;1:564-569) and Hepatitis G virus (Linnen et al., Science, 1996;271:505-508) are single-stranded RNA viruses thought to be isolates of the same virus (Zuckerman, Lancet, 1996;347:558-559). In the current report, Casteling et al. refer to this virus as GB virus C (GBV-C).

Little information is available about the epidemiology, mode(s) of transmission, and pathology associated with GBV-C, and reports have been conflicting, Casteling et al. noted.

"This is the first report from South Africa that describes the prevalence and epidemiology of GBV-C infection in this country using RT-PCR [reverse-transcriptase polymerase chain reaction] techniques to detect GBV-RNA in blood donors and groups at high risk for parenteral exposure," Casteling et al. wrote.

The researchers studied the prevalence of GBV-C infection in voluntary blood donors and in groups at high risk for parenteral exposure to infectious agents. The high risk groups included chronic renal failure on hemodialysis, renal transplant patients, and hemophiliacs from the Johannesburg General Hospital in Gauteng, South Africa. The blood specimens from the blood donors were obtained from the South African Blood Transfusion Service in Gauteng.

Of the blood donors, 11.1 percent were positive for GBV-C, compared to 23.8 percent of hemodialysis patients, 23.5 percent of hemophiliacs, and 41.2 percent of the renal transplant patients.

Casteling et al. also measured serological markers for Hepatitis B virus (HBV) and Hepatitis C virus (HCV) as indicators of other hepatitis viruses with important parenteral transmission routes.

Of the GBV-C positive blood donors, 3.6 percent also were HBsAg positive and none were HCV positive. The GBV-C positive patients on hemodialysis were not positive for HBsAg or antibodies to HCV, however, they showed evidence of past infection with HBV, because 40 percent were anti-HBc positive. The greatest proportion of HCV positive individuals, 91.3 percent, was found in the group of hemophiliacs; none were HBsAg positive, but 39.1 percent had anti-HBc. In the GBV-C renal transplant patients, 4 percent had HBsAg, 13.3 percent had anti-HBc, and 2.1 percent had antibodies to HCV, the researchers reported.

Finding such a high prevalence (11.1 percent) of GBV-C in blood donors in Gauteng was noteworthy, Casteling et al. said. The figure is considerably higher than figures reported for other areas of the world, except for West Africa at 14.2 percent (Dawson et al., Journal of Medical Virology, 1996;50:97-103) and 12.9 percent in paid blood donors in the United States (Dawson et al., 1996). The next highest reported figure is 4.7 percent in Germany (Herringlake et al., Lancet, 1996;348:1626-1629).

This research was funded by grant number 96/7 from the Poliomyelitis Research Foundation.

The corresponding author for this study is Alison Casteling, National Institute for Virology, Private Bag X4, Sandringham, 2131, South Africa.

- by Cathy Clark

Site Topics

  • HCV Symptoms

    You'll find links to a comprehensive symptoms list, as well as various studies and discussions about Hepatitis C symptoms.

  • Lab Tests

    What they are and what they mean. Helps you interpret & understand all the various hepatitis lab tests likely to be encountered.

  • Hepatitis C Genotypes

    Learn about Hepatitis C Genotypes and their variants.

  • Viral Load

    Provides detailed information on how to analyze and interpret viral load numbers as well as a link to a convenient Viral Load Chart.

  • What is...?

    Learn more about various Hepatitis C related topics, including HCV, Ascites, Biopsies, and much more.

  • HCV Medicines

    Numerous links to studies, info sheets, FAQs, and analysis of Ribavirin/Rebetron medicines.

  • Glossary

    Commonly used medical terms and definitions.

  • Hepatitis C Doctors

    A state-by-state and worldwide reference listing physicians who treat HCV, including an email link to submit your physician for inclusion.

  • Biopsy Info

    A comprehensive resource of information relating to the liver biopsy.

  • Cirrhosis

    Many discussions and analyses of cirrhosis, including causes, complications, pathology, symptoms, and much more.

  • Liver Cancer

    Liver Cancer/Hepatocellular Carcinoma studies, info sheets, FAQs, and analysis.

  • Liver Disease Medicines

    An exhaustive list of links to studies, info sheets, FAQs, and analysis of the various drugs used to treat liver disease.

  • Hep-Central Email List

    Sign up to learn about advances and breakthroughs in Hepatitis C research, including information about medical and complementary treatments.

  • HCV Links

    Convenient links to other sites external to Hepatitis-Central.

  • HCV Transmission

    Information about the transmission of Hepatitis C.

  • HCV Natural Remedies

    A number of herbal products useful in the management of liver disease.

  • HCV Books

    Recommended reading for those interested in hepatitis information.

  • Hepatitis C Forum

    A Bulletin Board for discussions on hepatitis, treatments, etc.

  • Hepatitis C Activism

    An easy way to get involved in urging our government to do more for Hepatitis C awareness and treatment research.

Advertisement

Advertisement